Home / Market News / $TXG
benzinga Corporate Catalyst Impact 65/100 ● neutral

Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

Sep 28, 2026, 12:10 PM UTC · Primary ticker $TXG

Argus Research has initiated coverage on 10x Genomics (TXG) with a 'Buy' rating and a price target of $110. This analyst coverage and price target announcement could generate positive sentiment and increased investor interest in the stock.

Argus Research has initiated coverage on 10x Genomics, assigning a 'Buy' rating and a $110 price target. This event is significant because new analyst coverage, especially with a positive rating and a specific price target, often acts as a catalyst for a stock. It signals to the market that a reputable research firm sees upside potential, which can attract new investors and increase trading volume. For traders, this presents a short-term opportunity for upward price movement due to increased investor confidence and potential buying pressure, though long-term performance will still depend on the company's fundamentals and execution.

$TXG positive New Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.